84 related articles for article (PubMed ID: 11056955)
1. U-50,488H, a kappa opioid receptor agonist, is a more potent blocker of cardiac sodium channels than lidocaine.
Pugsley MK; Yu EJ; Goldin AL
Proc West Pharmacol Soc; 2000; 43():47-50. PubMed ID: 11056955
[No Abstract] [Full Text] [Related]
2. kappa -opioid receptor stimulation induces arrhythmia in the isolated rat heart via the protein kinase C/Na(+)-H(+)exchange pathway.
Bian JS; Pei JM; Cheung CS; Zhang WM; Wong TM
J Mol Cell Cardiol; 2000 Aug; 32(8):1415-27. PubMed ID: 10900168
[TBL] [Abstract][Full Text] [Related]
3. [Specificity of the anti-arrhythmic effect of kappa1-opioid receptor agonists].
Ugdyzhekova DS; Maslov LN; Krylatov AV; Lishmanov IuB; Tam SV
Eksp Klin Farmakol; 2001; 64(4):17-20. PubMed ID: 11589101
[TBL] [Abstract][Full Text] [Related]
4. The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons.
Su X; Castle NA; Antonio B; Roeloffs R; Thomas JB; Krafte DS; Chapman ML
Anesth Analg; 2009 Aug; 109(2):632-40. PubMed ID: 19608841
[TBL] [Abstract][Full Text] [Related]
5. Delayed uncoupling is related to cardioprotection induced by kappa-agonist U-50,488H in rat heart.
Chen BP; Mao HJ; Fan FY; Bruce IC; Xia Q
Scand Cardiovasc J; 2005 Dec; 39(6):375-82. PubMed ID: 16352491
[TBL] [Abstract][Full Text] [Related]
6. An electrophysiological basis for the antiarrhythmic actions of the kappa-opioid receptor agonist U-50,488H.
Pugsley MK; Saint DA; Walker MJ
Eur J Pharmacol; 1994 Aug; 261(3):303-9. PubMed ID: 7813552
[TBL] [Abstract][Full Text] [Related]
7. Nonopioid actions of U50,488 enantiomers contribute to their peripheral cutaneous antinociceptive effects.
Joshi SK; Gebhart GF
J Pharmacol Exp Ther; 2003 Jun; 305(3):919-24. PubMed ID: 12626643
[TBL] [Abstract][Full Text] [Related]
8. Anti-arrhythmic effects of kappa-opioid receptor and its changes in ischemia and reperfusion.
Jin-Cheng L; Wen Y; Zhao Y; Quan-Yu Z; Shu-Miao Z; Hai-Tao G; Hui B; Yue-Min W; Xin S; Liang C; Qin C; Shi-Qiang Y; Kaye AD; Ding-Hua Y; Jian-Ming P
Arch Med Res; 2008 Jul; 39(5):483-8. PubMed ID: 18514092
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of kappa-opioid receptor reduces isoprenaline-induced cardiac hypertrophy and fibrosis.
Yin W; Zhang P; Huang JH; Zhang QY; Fan R; Li J; Zhou JJ; Hu YZ; Guo HT; Zhang SM; Wang YM; Kaye AD; Gu CH; Liu JC; Cheng L; Cui Q; Yi DH; Pei JM
Eur J Pharmacol; 2009 Apr; 607(1-3):135-42. PubMed ID: 19233160
[TBL] [Abstract][Full Text] [Related]
10. Vasorelaxing effect of U50,488H in pulmonary artery and underlying mechanism in rats.
Sun X; Ma S; Zang YM; Lu SY; Guo HT; Bi H; Wang YM; Ma H; Ma XL; Pei JM
Life Sci; 2006 Apr; 78(21):2516-22. PubMed ID: 16336977
[TBL] [Abstract][Full Text] [Related]
11. Arylacetamide kappa-opioid receptor agonists produce a tonic- and use-dependent block of tetrodotoxin-sensitive and -resistant sodium currents in colon sensory neurons.
Joshi SK; Lamb K; Bielefeldt K; Gebhart GF
J Pharmacol Exp Ther; 2003 Oct; 307(1):367-72. PubMed ID: 12954815
[TBL] [Abstract][Full Text] [Related]
12. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
13. Contralateral, ipsilateral and bilateral treatments with the kappa-opioid receptor agonist U-50,488H in mononeuropathic rats.
Bileviciute-Ljungar I; Spetea M
Eur J Pharmacol; 2004 Jun; 494(2-3):139-46. PubMed ID: 15212967
[TBL] [Abstract][Full Text] [Related]
14. Pro- and anti-arrhythmic effects of a kappa opioid receptor agonist: a model for the biphasic action of a local hormone in the heart.
Yu X; Zhang W; Bian J; Wong TM
Clin Exp Pharmacol Physiol; 1999 Oct; 26(10):842-4. PubMed ID: 10549419
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory effects of contralateral administration of the kappa-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis.
Bileviciute-Ljungar I; Saxne T; Spetea M
Rheumatology (Oxford); 2006 Mar; 45(3):295-302. PubMed ID: 16249243
[TBL] [Abstract][Full Text] [Related]
16. Differential cardiovascular and renal responses produced by microinjection of the {kappa}-opioid U-50488H [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) methane sulfonate] into subregions of the paraventricular nucleus.
Gottlieb HB; Varner KJ; Kenigs VA; Cabral AM; Kapusta DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):678-85. PubMed ID: 15381735
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation.
Li JG; Zhang F; Jin XL; Liu-Chen LY
J Pharmacol Exp Ther; 2003 May; 305(2):531-40. PubMed ID: 12606694
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms involved in the hypotensive effect of a kappa-opioid receptor agonist in hypertensive rats.
Guo HT; Zhang RH; Huang LY; Li J; Liu YL; Bi H; Zhang QY; Wang YM; Sun X; Ma XL; Cheng L; Liu JC; Yu SQ; Yi DH; Pei JM
Arch Med Res; 2007 Oct; 38(7):723-9. PubMed ID: 17845890
[TBL] [Abstract][Full Text] [Related]
19. U-50,488 and the kappa receptor. Part II: 1991-1998.
Szmuszkovicz J
Prog Drug Res; 1999; 53():1-51. PubMed ID: 10616295
[TBL] [Abstract][Full Text] [Related]
20. Prospects of Using of κ-Opioid Receptor Agonists U-50,488 and ICI 199,441 for Improving Heart Resistance to Ischemia/Reperfusion.
Tsibulnikov SY; Maslov LN; Mukhomedzyanov AV; Krylatov AV; Tsibulnikova MR; Lishmanov YB
Bull Exp Biol Med; 2015 Oct; 159(6):718-21. PubMed ID: 26519268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
